EGFR and lung cancer: We conclude that RNA interference by siRNA oligonucleotides should be further explored and developed as a therapeutic modality in the treatment of EGFR mutant lung cancer and also including KRAS mutant lung cancer, and lung cancers containing the resistance mutations T790M or downstream pathway activation such as PTEN inactivation.